[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rejection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rejection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,75,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100632645","graft-20-a-multimodal-prospective-approach-to-define-the-mechanisms-and-clinical-features-of-acute-and-chronic-rejection-in-lung-transplantation-100632645",false,"NCT07516379","GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with study procedures and availability for the duration of the study.\n2. Male or female, aged 18 - 75 years of age.\n3. Have progressive lung disease or undergone or being evaluated for lung transplantation.\n4. Ability of subjects to understand the informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1\\. Pregnancy or lactation","ALL","18 Years","75 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Background:\n\nLung transplants can save lives, but the procedure has risks. Some people develop donor-specific antibodies (DSA) after the procedure-that is, their bodies create proteins that treat the new lungs as foreign and mount an immune response against them. This is called rejection. But not everyone who has a transplant develops DSA, and not everyone who has DSA develops rejection. Researchers want to understand why.\n\nObjective:\n\nTo collect data to try to find out why some people develop rejection after lung transplants while others do not.\n\nEligibility:\n\nPeople aged 18 to 75 years who have progressive lung disease or undergone or may undergo a lung transplant.\n\nDesign:\n\nParticipants will have clinic visits every 3 to 6 months for up to 4 years. Some visits might require an overnight stay.\n\nEach visit will include multiple tests and procedures:\n\nPhysical exam with blood and urine tests. Some blood will be used for genetic testing.\n\nImaging scans. Participants will have 2 types of scan to get images of their lungs. For one, they will have a contrast agent given through a tube inserted into a vein.\n\nSix-minute walk test. Participants will walk back and forth in a hallway at their own pace. Researchers will check on how their body responds.\n\nLung function test. Participants will breathe into a tube connected to a machine.\n\nTwo other tests are optional:\n\nBronchoscopy with washings (lavage). A long tube with a light will be threaded down through the participant s nose or mouth and into their lungs.\n\nEndomicroscopy. During the bronchoscopy a tiny camera may be used to take pictures inside the lungs.\n\n...",[24,25,26],"Lung Transplant","End Stage Lung Disease","Rejection",[24,26],"RECRUITING","2026-06-10",{"date":31,"type":32},"2026-06-11","ACTUAL",{"date":34,"type":32},"2026-05-11",{"date":36,"type":20},"2032-03-27",{"name":38,"class":39},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":5},"100579855","ttv-based-management-of-long-term-immunosuppression-in-kidney-transplantation-100579855","NCT06829719","TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation","Personalization of Maintenance Immunosuppression Based on TTV Viral Load to Prevent Long-term Complications in Renal Transplantation","TAOIST","Inclusion Criteria:\n\n* Adult ≥ 18 years-old\n* Recipient of a kidney allograft (third graft at most)\n* 12 to 48 months post-transplantation\n* Stable graft function (defined as: delta creatininemia over the previous 6 months \\\u003C 20% and proteinuria \\\u003C 30mg\u002Fmmol)\n* On maintenance immunosuppression, which includes CNI (cyclosporin or tacrolimus) and MMF (Cellcept or Myfortic) with or without corticosteroids\n* Detectable TTV DNAemia at enrollment\n* No circulating DSA in solid phase assay\n* Undetectable BKV DNAemia at enrollment\n* Written informed consent\n\nExclusion Criteria:\n\n* Recipient of an HLA identical graft\n* Mutiple organ transplantation or functional transplant other than kidney\n* Maintenance immunosuppression that includes a mTOR inhibitor, belatacept or imurel\n* Presence of histological sign of active rejection (i+t \\> 2 and g+cpt \\> 2) on graft biopsy performed within 3 months before enrollment\n* Uncontrolled infection at inclusion\n* Infection requiring hospitalization within 3 months before inclusion\n* Diagnosis of a cancer of interest between the (current) transplantation and inclusion\n* Pregnant, unwillingness to practice adequate contraception or patient with a pregnancy plan during 3 years of study\n* Person not affiliated to a social security scheme or beneficiary of a similar scheme\n* Person subject to a legal protection measure (guardianship, curatorship) or deprived of liberty",{"count":50,"type":20},600,"INTERVENTIONAL",[53],"NA","Long-term outcomes in kidney transplantation remain a significant challenge, as complications such as donor-specific antibodies (DSA), antibody-mediated rejection, infections, and cancer increasingly threaten graft and patient survival over time. The development of non-invasive biomarkers to guide the management of therapeutic immunosuppression beyond the first year post-transplantation is therefore a crucial unmet need.\n\nTorque Teno Virus (TTV), a non-pathogenic virus with a high prevalence worldwide, has emerged as a promising biomarker in this context. Its replication inversely reflects immune control by T cells, correlating with the depth of therapeutic immunosuppression. Additionally, its slow replication kinetics make TTV DNAemia a useful marker for evaluating patient adherence to immunosuppressive treatments.\n\nThe TAOIST study tests whether longitudinal monitoring of TTV DNAemia every six months, starting from the second year after transplantation, can guide the personalization of immunosuppressive therapy. The primary endpoint is the time to the first occurrence of complications linked to inadequate immunosuppression, including dnDSA, biopsy-proven rejection, infection, cancer, or graft loss. Secondary objectives include evaluating the acceptability of TTV DNAemia among healthcare professionals and assessing its cost-effectiveness compared to standard care. An ancillary objective examines the link between TTV DNAemia and the immunosuppressant possession ratio (IPR) to explore its potential as a marker of treatment adherence.",[56,57,26,58],"Infection","Cancer","Kidney Transplantation",[60,61,62,63,64],"TTV","Biomarker","immunosuppression","precision medicine","kidney transplantation","2026-05-22",{"date":67,"type":32},"2026-05-27",{"date":69,"type":32},"2025-04-23",{"date":71,"type":20},"2031-02-02",{"name":73,"class":74},"Hospices Civils de Lyon","OTHER",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":15,"minAge":16,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":51,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100412460","early-phase-1-the-role-of-the-opioid-system-in-placebo-effects-on-pain-and-social-rejection-100412460","NCT04650841","The Role of the Opioid System in Placebo Effects on Pain and Social Rejection","Inclusion Criteria:\n\n* Adults aged 18-55 years\n* No current psychiatric or major neurological diagnosis\n* No reported substance abuse within the last six months\n* Are capable of performing experimental tasks (e.g., are able to read, able to cooperate with fMRI examination)\n* Are fluent or native speakers of English\n* No current or recent history of pathological pain or reported neurological disorders.\n* Having abstained from alcohol and substance use for 48 hours\n* Passed fMRI safety screener\n* Experienced a recent unwanted breakup of a romantic relationship\n\nExclusion Criteria:\n\n* Current presence of pain\n* Current or past history of primary psychiatric disorder\n* Current or past history of psychoactive substance abuse or dependence\n* Dementias\n* Movement disorders except familial tremor\n* CNS infection\n* CNS vasculitis, inflammatory disease or autoimmune disease\n* CNS demyelinating disease (e.g. multiple sclerosis)\n* Space occupying lesions (mass lesions, tumors)\n* Congenital CNS abnormality (e.g. cerebral palsy)\n* Seizure disorder\n* History of closed head trauma with loss of consciousness\n* History of cerebrovascular disease (stroke, TIAs)\n* Abnormal MRI (except changes accounted for by technical factors or UBOs)\n* Neuroendocrine disorder (e.g., Cushings disease)\n* Uncorrected hypothyroidism or hyperthyroidism\n* Current or past history of cancer; Recent history (within two years) of myocardial infarction, severe cardiovascular disease, or currently active cardiovascular disease (e.g. angina, cardiomyopathy)\n* Uncontrolled hypertension or hypotension\n* Chronic pain syndromes\n* Chronic fatigue syndromes\n* Subjects unable to tolerate the scanning procedures (e.g., claustrophobia)\n* Prior treatment within the last month with any of the following: antidepressants, mood stabilizers, glucocorticoids, opiates\n* Prior treatment with any of the following: antipsychotics, isoniazid, centrally active antihypertensive drugs (e.g. clonidine, reserpine)\n* Metal in body or prior history working with metal fragments (e.g., as a machinist)\n* For women, pregnancy\n* Any other contraindications for MRI examination (e.g., metallic implants such as pacemakers, surgical aneurysm clips, or known metal fragments embedded in the body)\n* Claustrophobia",true,"55 Years",{"count":84,"type":20},60,[86],"EARLY_PHASE1","The current study probes the involvement of the opioid system in placebo effects on social pain, using the opioid antagonist naloxone. 60 participants who recently experienced an unwanted breakup will experience rejection-related stimuli and receive painful heat and pressure stimuli during fMRI scanning. Participants will be randomized to receive either a naloxone or saline nasal spray, and be informed that the spray is either saline, or an effective pain and negative emotion reducing agent.",[89,26,90],"Pain","Placebo Effect","NOT_YET_RECRUITING","2025-12-02",{"date":94,"type":32},"2025-12-09",{"date":96,"type":20},"2026-09-01",{"date":98,"type":20},"2027-03-01",{"name":100,"class":74},"Trustees of Dartmouth College",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100543101","detection-of-circulating-kidney-dna-in-kidney-transplant-patients-facing-an-episode-of-graft-rejection-100543101","NCT06351488","Detection of Circulating Kidney DNA in Kidney Transplant Patients Facing an Episode of Graft Rejection","DART-RREGREF","Inclusion Criteria:\n\n* Age ≥ 18 ans\n* Patient living with at least one functioning kidney graft\n* Summoned to perform a kidney biopsy for cause\u002Findication at the Pitié Salpêtrière Hospital or at the Necker Hospital\n* Having been informed of the study and not opposing the study\n* Benefiting from a social security system (excluding AME)\n\nExclusion Criteria:\n\n* Under legal protection measure (curatorship or guardianship, under judicial protection).",{"count":109,"type":20},319,"In France, 3,500 kidney transplants are carried out per year; and 40,000 people succeed in 2019 with a kidney transplant. Despite regular medical monitoring, nearly 30% of transplant patients will develop rejection. Currently, only solid biopsy of the graft makes it possible to establish the diagnosis of graft rejection, and to characterize its cellular origin based on the Banff classification.\n\nSeveral studies have shown the possibility of identifying the tissue origin of DNA circulating in the blood, in healthy subjects, on the basis of the epigenetic properties of circulating DNA. In addition, in kidney transplant subjects, an increase in the quantity of circulating DNA originating from the graft in the blood and urine has been shown as well as an increase in urinary chemokine levels during renal dysfunction (notably dismiss). Thus, the company CGenetix in partnership with INSERM units 1155 and 1151 is developing a method to identify and characterize kidney transplant rejection early, through the detection of epigenetic biomarkers on circulating DNA targeting different fractions of the kidney (glomerular, tubular, peritubular capillary and vascular). The main objective is to study the diagnostic performance of the quantity of DNA of renal origin in kidney transplant patients in the blood and in the urine (expressed in copies\u002Fml) for the diagnosis of type Rejection mediated by kidneys. antibody (ABMR) established by kidney graft biopsy (gold standard) and according to the Banff 2022 classification.",[112,26],"Kidney Transplant",[114,115,116],"Graft rejection","renal circulating DNA","performance of the diagnostic test","2024-12-16",{"date":119,"type":32},"2024-12-19",{"date":121,"type":32},"2024-08-21",{"date":123,"type":20},"2026-02-11",{"name":125,"class":74},"Assistance Publique - Hôpitaux de Paris",3]